Test Drive werwer | Page 12

There are a few key factors for why that is so. With overall M&A levels declining by a significant amount from 4Q 2015 thus far, corporate buyers are pulling back. The deals being closed simply have to be much more justifiable than what has been the case previously, with strategics hunkering down somewhat in anticipation of growth headwinds. But in a positive sign, the incentives to essentially sidestep up-and-coming innovators, add talent, grow patent portfolios and more can be resilient, if not so imperative as to do more than maintain a subdued level of startup acquisitions. Judging by the median U.S. acquisition/buyout size of $90 million in 1Q, it’s clear corporate and financial buyers are still able to justify some hefty price tags. If a shakeout in valuations produces a crop of troubled startups, that could render their acquisitions more attractive to strategics, which could boost exits. Even in an uncertain climate, corporate buyers will pay up for key enhancing technologies, while bargains will always be welcome. And as for the IPO pipeline—as mentioned in our recent VC Liquidity Report—until the waters calm enough to be braved by an intrepid few, the drought should continue. Even corporate buyers are quite shy U.S. venture-backed exits (#) by type Only M&A has sustained into 2016 in terms of value U.S. venture-backed exits ($B) by type 1,200 $100 Acquisition IPO Buyout Acquisition $90 1,000 IPO $80 Buyout $70 800 $60 600 $50 $40 400 $30 $20 200 $10 0 $0 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016* 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016* Source: PitchBook *As of 3/31/2016 Source: PitchBook *As of 3/31/2016 But of the exits that occurred, many were lucrative Median venture-backed exit size ($M) in U.S. Unsurprisingly, software remained popular U.S. venture-backed exits (#) by sector $100 1,200 Commercial Services $90 $90 Consumer Goods & Recreation 1,000 $80 $77 $70 $60 $71* $51 $50 $40 Energy 800 Healthcare Svcs/Supp./Sys. 600 IT Hardware Media 400 $30 IPO Pharma & Biotech Source: PitchBook *As of 3/31/2016. Note, due to the scarcity of IPOs, this number is skewed considerably. 12 P I TC H B O O K 1 Q 201 6 U. S . V E N T U R E I N D U S T RY R E P O R T 2015 2014 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016* 2013 $0 2012 0 2016* Acquisition/Buyout 2011 $10 Other 200 2010 $20 Software Source: PitchBook *As of 3/31/2016